Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Zirconium-immuno-positron emission tomography (Zr-immuno-PET) is used for assessment of target status to guide antibody-based therapy. We aim to determine the relation between antibody tumor uptake and target concentration to improve future study design and interpretation.
Methods: The relation between tumor uptake and target concentration was predicted by mathematical modeling of Zr-labeled antibody disposition in the tumor. Literature values for trastuzumab kinetics were used to provide an example.
Results: Zr-trastuzumab uptake initially increases with increasing target concentration, until it levels off to a constant value. This is determined by the total administered mass dose of trastuzumab. For a commonly used imaging dose of 50 mg Zr-trastuzumab, uptake can discriminate between immunohistochemistry score (IHC) 0 versus 1-2-3.
Conclusion: The example for Zr-trastuzumab illustrates the potential to assess target expression. The pitfall of false-positive findings depends on the cut-off to define clinical target positivity (i.e., IHC 3) and the administered mass dose.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380210 | PMC |
| http://dx.doi.org/10.1186/s13550-021-00813-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blood proteomic signatures associated with disease activity in Inflammatory Bowel Diseases.
J Crohns Colitis
September 2025
Université de Paris, INSERM U1342, Institut de Recherche Saint-Louis, Paris, France.
Background And Aims: Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), remain heterogeneous disorders with variable response to biologics. Post-operative recurrence in CD is common despite surgery and prophylactic biotherapies. Understanding the inflammatory mediators associated with recurrence and treatment response could pave the way for personalized strategies.
View Article and Find Full Text PDFCombinatorial targeting of PI3K/AKT pathway with BKM120 increases cisplatin sensitivity and apoptotic response in A549 lung cancer cells.
Cell Mol Biol (Noisy-le-grand)
September 2025
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Despite significant advancements in the treatment of non-small cell lung cancer (NSCLC) using conventional therapeutic methods, drug resistance remains a major factor contributing to disease recurrence. In this study, we aimed to explore the potential benefits of combining PI3K inhibition with Cisplatin in the context of NSCLC-derived A549 cells. Human non-small cell lung cancer A549 cells were cultured and treated with BKM120, cisplatin, or their combination.
View Article and Find Full Text PDFPublished Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients.
Target Oncol
September 2025
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Background: Population pharmacokinetic models can potentially provide suggestions for an initial dose and the magnitude of dose adjustment during therapeutic drug monitoring procedures of imatinib. Several population pharmacokinetic models for imatinib have been developed over the last two decades. However, their predictive performance is still unknown when extrapolated to different populations, especially children.
View Article and Find Full Text PDF"Engineering Rifampicin-Encapsulated Inhalable Microparticles for Precision Tuberculosis Therapy: In Vivo Distribution and Therapeutic Evaluation".
J Drug Target
September 2025
Department of Pharmaceutics, ShriRam College of Pharmacy, Banmore, Morena-476444, Madhya Pradesh, India.
Tuberculosis (TB) continues to cause significant global mortality, highlighting the need for improved drug delivery systems. The objective of this paper focuses in describing the formulation, optimization and in vivo assessment of rifampicin encapsulated PLGA microparticles for site-specific inhalation therapy. Microparticles for inhalation were produced by spray drying, and the DoE methodology was applied to reach the most suitable aerodynamic properties (mass median aerodynamics diameter (MMAD) 2.
View Article and Find Full Text PDFA Porcine Monoclonal Antibody Targeting a Conserved GP4 Epitope Protects against In Vivo Infection via the Induction of Broad-Spectrum PRRSV Neutralization.
Adv Sci (Weinh)
September 2025
College of Veterinary Medicine, Northwest A&F University, Yangling, 712100, China.
Porcine reproductive and respiratory syndrome virus (PRRSV) imposes substantial economic losses on global swine production. While modified live vaccines remain the primary prevention tool, their efficacy is compromised by the genetic variability of PRRSV. This study developed a broadly neutralizing monoclonal antibody (mAb) that targets a conserved viral epitope as an alternative therapeutic strategy.
View Article and Find Full Text PDF